Valuation dashboard for Ernexa Therapeutics Inc. (ERNA) with P/E N/A, P/B 1.45, EV/EBITDA 0.19 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $3.91, ERNA has negative trailing earnings (P/E not meaningful) and an ROE of -305.85%. Market capitalisation stands at $1M.
Balance sheet quality for ERNA: current ratio of 1.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.45 |
| EV / EBITDA | 0.19 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $1.93 |
| vs Current Price | -50.7% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ERNA | Ernexa Therapeutics Inc. | $1M | 1.45 | -305.9% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $3.91 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -305.85% |
| Return on Invested Capital | -328.05% |
| Return on Assets | -194.09% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADAP · AEMD · AEON · DWTX · LNAI · MBRX · MPLT
Explore sector: Healthcare · Biotechnology
More sections of ERNA: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks